# Zai Lab (Shanghai) Co., Ltd. clinical trials: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Zai Lab (Shanghai) Co., Ltd. as lead sponsor, 8 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Zai Lab (Shanghai) Co., Ltd.: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/zai-lab-shanghai-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 8
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 3, 2026 | NCT07802132 | A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of... | Zai Lab (Shanghai) Co., Ltd. | Observational | Not yet recruiting | Schizophrenia Disorder | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802132) |
| August 31, 2026 | NCT07796100 | A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint... | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Not yet recruiting | Extensive-Stage Small Cell Lung Cancer | 530 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796100) |
| June 22, 2026 | NCT07658482 | A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658482) |
| January 29, 2026 | NCT07374848 | Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Recruiting | Solid Tumors, Sarcomas | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07374848) |
| November 19, 2025 | NCT07235384 | A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to... | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Recruiting | Atopic Dermatitis (AD) | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07235384) |
| October 20, 2025 | NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Recruiting | Small-cell Lung Cancer | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218146) |
| October 8, 2025 | NCT07211776 | A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Active not recruiting | Thyroid Eye Disease (TED) | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07211776) |
| March 20, 2025 | NCT06885281 | A Study of ZL-1310 in Participants With Selected Solid Tumors | Zai Lab (Shanghai) Co., Ltd. | Phase 1/2 | Recruiting | Solid Tumors | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06885281) |
| December 21, 2023 | NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Recruiting | SCLC | 339 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06179069) |
| May 19, 2023 | NCT05866354 | To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Completed | Solid Malignancies | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05866354) |
| March 3, 2022 | NCT05263986 | The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Unknown | Advanced or Metastatic Solid Tumor | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05263986) |
| December 4, 2020 | NCT04653038 | A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Terminated | Unresectable, Recurrent or Metastatic Melanoma, Untreated Mucosal or Acral Lentiginous Melanoma | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04653038) |
| November 18, 2020 | NCT04633122 | A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Completed | Gastrointestinal Stromal Tumor(GIST) | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04633122) |
| May 21, 2020 | NCT04398108 | A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Completed | HER2 Positive Metastatic Breast Cancer | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04398108) |
| May 18, 2020 | NCT04392102 | A Study of Niraparib in Patients With Relapsed Ovarian Cancer | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Completed | Ovarian Cancer | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04392102) |
| February 25, 2020 | NCT04282980 | A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Completed | Gastrointestinal Stromal Tumors | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04282980) |
| February 10, 2020 | NCT04262804 | A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Unknown | Breast Cancer Metastatic | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04262804) |
| February 6, 2020 | NCT04257617 | A Trial of ZL-1201 in Subjects With Advanced Cancer | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Completed | Advanced Cancer | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04257617) |
| December 26, 2019 | NCT04212221 | MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients | Zai Lab (Shanghai) Co., Ltd. | Phase 1/2 | Terminated | Advanced Hepatocellular Carcinoma (HCC) | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04212221) |
| November 26, 2019 | NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Terminated | Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma, Endometrial Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04178460) |
| October 17, 2018 | NCT03709316 | A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Unknown | Ovarian Cancer | 384 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03709316) |
| October 15, 2018 | NCT03705156 | Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Unknown | Platinum-sensitive Relapsed Ovarian Cancer | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03705156) |
| June 11, 2018 | NCT03551171 | The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer | Zai Lab (Shanghai) Co., Ltd. | Phase 1 | Completed | Ovarian Cancer | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03551171) |
| May 4, 2018 | NCT03516084 | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell... | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Terminated | Extensive-stage Small Cell Lung Cancer | 185 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03516084) |
| May 4, 2018 | NCT03516071 | A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Completed | Hepatocellular Carcinoma (HCC) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03516071) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 2 |
| Phase 2 | 5 |
| Phase 3 | 6 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 8 |
| Recruiting | 5 |
| Unknown | 4 |
| Terminated | 4 |
| Not yet recruiting | 3 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Ovarian Neoplasms | 3 |
| Small Cell Lung Carcinoma | 3 |
| Gastrointestinal Stromal Tumors | 2 |
| Neoplasm Metastasis | 2 |
| Schizophrenia | 1 |
| Dermatitis, Atopic | 1 |
| Sarcoma | 1 |
| Hematologic Neoplasms | 1 |
| Recurrence | 1 |
| Melanoma | 1 |
| Carcinoma, Hepatocellular | 1 |
| Stomach Neoplasms | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Endometrial Neoplasms | 1 |
| Graves Ophthalmopathy | 1 |
| Breast Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [EMS training centers in the United States](https://specstream.ai/data/businesses/ems-training-centers/united-states)
- [Hydraulic equipment suppliers in the United States](https://specstream.ai/data/businesses/hydraulic-equipment-suppliers/united-states)
- [Nepalese restaurants in the United States](https://specstream.ai/data/businesses/nepalese-restaurants/united-states)
- [Remodeling contractors in the United States](https://specstream.ai/data/businesses/remodeling-contractors/united-states)
- [Uniform stores in the United States](https://specstream.ai/data/businesses/uniform-stores/united-states)
- [B2B oil and gas extraction companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-extraction-companies/united-states)
